Akari Therapeutics plc ADR (0.01 USD) financials
$9.72−0.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$17.3M | -$21.6M | -$16.8M | -$23.1M | -$17.2M | -$18.0M | -$17.0M | -$20.8M | -$37.8M | -$27.2M |
| Net income | -$17.3M | -$19.8M | -$10.0M | -$17.7M | -$17.4M | -$17.1M | -$16.8M | -$20.6M | -$35.4M | -$18.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-8.00 | $-8.00 | $-8.00 | $-24.00 | $-16.00 |
| EBITDA | -$12.1M | -$16.6M | -$16.8M | -$23.1M | -$17.2M | -$18.0M | -$16.9M | -$20.7M | -$35.0M | -$27.2M |
| Operating cash flow | -$10.6M | -$12.6M | -$16.4M | -$21.5M | -$18.8M | -$17.0M | -$12.9M | -$22.8M | -$31.6M | -$24.6M |
| Free cash flow | -$10.6M | -$12.6M | -$16.4M | -$21.5M | — | — | — | — | -$31.6M | -$24.7M |
| Diluted shares | 1,683.2M | 597.2M | 244.7M | 156.1M | 5.4M | 3.9M | 2.3M | 1.9M | 1.6M | 1.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.2M | $2.6M | $3.8M | $13.3M | $9.4M | $14.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $754.0K | $1.4M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $47.9M | $50.6M | $4.4M | $13.8M | $11.6M | $14.6M |
| Total liabilities | $19.6M | $28.3M | $4.6M | $12.0M | $6.1M | $5.2M |
| Shareholders' equity | $28.3M | $22.2M | -$229.0K | $1.8M | $5.6M | $9.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology